Evidence map›Paper›PMID 30669787›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2018

[Safety and efficacy of DCV-based DAAs therapy for chronic HCV infection in China].

J Y Wei, D N Lin, Z B Wu, J Y Zhu, Z X Zhao, Y Y Mei, C S Lin, J Zhang, X H Zhang

Open access · greenAbstract read
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. [Analysis of baseline characteristics and treatment status of hepatitis C in sentinel hospitals from 2017 to 2019].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

J Y WeiDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
D N Lin
Z B Wu
J Y Zhu
Z X Zhao
Y Y Mei
C S Lin
J Zhang
X H Zhang
Sun Yat-sen University · CN

Funding

Optimized treatment and establishment of standardized follow-up system of chronic HCV infection, and early diagnosis of HCV-related liver cancer in Guangdong Province 2014B020212025
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

GenotypeAntiviral AgentsCarbamatesChinaDrug Therapy, CombinationHepacivirusHepatitis C, ChronicHumansImidazolesNeoplasm Recurrence, LocalProspective StudiesPyrrolidinesTreatment OutcomeValineAntiviral AgentsCarbamatesdaclatasvirImidazolesPyrrolidinesValineDaclatasvirDirect-acting antiviral agentHepatitis C, chronicSafetyTherapy

Identifiers

PMID30669787
PMCPMC12813447
OpenAlexW2998927032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.